<DOC>
	<DOCNO>NCT00386334</DOCNO>
	<brief_summary>To evaluate long-term safety efficacy eszopiclone administer 12 week elderly subject primary chronic insomnia.Administration eszopiclone 2 mg daily bedtime 12 week elderly subject diagnosis primary chronic insomnia safe well tolerate , improve subjective sleep measure , improve measure Quality Life next day insomnia symptom , significant withdrawal central nervous system adverse event rebound insomnia .</brief_summary>
	<brief_title>A Long-Term Safety Efficacy Study Eszopiclone Elderly With Primary Chronic Insomnia</brief_title>
	<detailed_description>A double-blind , randomize , placebo control , parallel group study eszopiclone elderly subject primary chronic insomnia . The study involve 9 visit subject participation approximately 18 week . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Male female subject primary chronic insomnia . Subject otherwise good general health , base screen physical examination medical history . Subject recent history know clinically significant abnormal laboratory finding .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>insomnia</keyword>
	<keyword>chronic</keyword>
	<keyword>primary</keyword>
</DOC>